

**Wanbury Limited**

**Regd. Office :** BSEL Tech Park, B-wing  
10<sup>th</sup> Floor, Sector-30 A,  
Opp. Vashi Railway Station,  
Vashi Navi Mumbai 400 703  
Maharashtra, INDIA  
Tel. : +91-22-6794 2222  
+91-22-7196 3222  
CIN L51900MH1988PLC048455  
Email : info@wanbury.com  
Website : www.wanbury.com

May 16<sup>th</sup>, 2024

BSE Limited P.J. Towers, Dalal Street Mumbai – 400001. <b>Script Code: 524212</b>	National Stock Exchange of India Ltd, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai -400051 <b>Script Code: WANBURY</b>
---	---

**Sub: Press release on Q4 & FY24 Financial Results**

Dear Sir/Madam,

Please find attached herewith copy of press release on Q4 & FY24 Financial Results.

This is for your information and record.

Thanking you.

Yours faithfully,  
**For Wanbury Ltd**



**Jitendra J. Gandhi**  
**Company Secretary**

Encl.: a/a.



## Wanbury Ltd. net profit up 696% (YOY) at Rs. 8.3 cr in Q4FY24

16<sup>th</sup> May, 2024, MUMBAI: Wanbury Ltd, one of India's fastest growing pharmaceutical company having a presence in API global market and domestic branded Formulation, announced its financial results for the fourth quarter and year ended March 31, 2024.

### Consolidated Q4 & FY24 Financial Highlights

(Rs in Crore)

Particulars	Q4 FY24	Q3 FY24	% QoQ	Q4 FY23	% YoY	FY24	FY23	% YoY
Revenue from Operations	139.4	145.5	-4.2%	133.0	4.8%	575.6	499.6	15.2%
EBITDA	19.1	21.8	-13%	12.1	57.7%	73.0	24.1	203.1%
EBITDA Margin (%)	13.7%	15.0%	-1.3%	9.1%	4.5%	12.7%	4.8%	7.9%
PAT	8.3	10.3	-18.6%	1.0	696%	30.4	(10.4)	392.4%
PAT Margin (%)	6.0%	7.0%	-1%	0.8%	5.2%	5.3%	(2.1%)	7.3%

The company registered a 15% growth in Revenue & 4 fold jump in its Net Profits on YOY basis. The growth in revenue is attributed to an increase in sales of key API products in Europe, Brazil, and China. The company's export quantity for key products has gained significant market share on a year-over-year basis. The overall capacity utilization in our two US FDA-approved plants for key products has exceeded 90% quarter-on-quarter due to robust demand and efficient plant operations. The company is also focusing on debottlenecking and planning capacity expansion for key products. Better inventory management and strategic contracts for critical raw materials, along with various strategic engineering and operational initiatives, led to productivity improvement, yield improvement, and overall profitability.

Commenting on the performance, **Mr Mohan Rayana, Director, Wanbury Ltd:** said, the company is confident of continuing this growth journey in the coming year by expanding the customer base and increasing the share of business with existing customers. This will be coupled with plant capacity expansion for key products, development of new APIs, and entry into new therapeutic segments in the formulation business. Multiple business transformation projects have been implemented to further enhance efficiency and productivity, laying the foundation for our next phase of growth.





### **About Wanbury Ltd.**

Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes: Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic acid, Paroxetine and various other products in pipeline. The company's clients include some of the leading global generic players.

In formulations, the company has a wide presence across major therapeutic categories like, cough and cold solutions, gynaecology, orthopaedics, nutraceuticals, gastro intestinal, anti-inflammatory, & analgesics.

For more details on Wanbury Ltd.: <https://www.wanbury.com/>

For further information please contact

**Jitendra J. Gandhi**

**Company Secretary,**

**Wanbury Limited**

BSEL Techpark, B' Wing, 10th Floor,  
Sector 30-A, Opp. Vashi Railway Station,  
Vashi, Navi Mumbai - 400703, India.

Tel: +91-22-6794 2222

Email: [jitendra.gandhi@wanbury.com](mailto:jitendra.gandhi@wanbury.com)

**Hanishi Shah / Anand Venugopal**

**Adfactors PR**

Oasis Complex, Kamala Mills Compound, City  
Hall, Pandurang Budhkar Marg, Lower Parel  
West, Mumbai – 400021

Tel: +91 9619059339 / +91 7021852071

Email: [hanishi.shah@adfactorspr.com](mailto:hanishi.shah@adfactorspr.com)

[anand.venugopal@adfactorspr.com](mailto:anand.venugopal@adfactorspr.com)

### **Disclaimer:**

*This document may contain statements which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.*

